Maestros Electronics & Telecommunications Systems Limited (METSL) is an established Indian technology firm specializing in the design, development, and manufacturing of high-precision electronic solutions. The company’s core competencies span **cardiology, gynecology, critical care, and financial inclusion**. Operating from a centralized facility in **Mahape, Navi Mumbai**, METSL serves as a critical supplier to the Indian healthcare infrastructure, particularly within the government and defense sectors. --- ### **Core Product Portfolio & Diagnostic Solutions** The company’s value proposition is built on a robust line of medical monitoring and diagnostic devices designed for high-stakes clinical environments. * **Cardiac Monitoring & Resuscitation:** * **METSL TFT Display Cardiac Monitor with Defibrillator**: Integrated emergency care systems. * **Defibrillator Monitor with External Pacing (Model: METSL TFT)**: Specialized units (PVMS No. 280608) for advanced life support. * **Electrocardiography (ECG):** * **METSL 12 Channels ECG Machine**: A flagship portable, lightweight computerized unit featuring simultaneous **12-lead acquisition**, auto-measurement parameters, and **A4 size thermal paper** printing. * **Patient Monitoring Systems:** * **Multipara Monitors**: Includes **2-channel TFT** preconfigured monitors and advanced units equipped with **NIBP (Non-Invasive Blood Pressure)** and dedicated **Neonatal/Pediatric Probes**. --- ### **Strategic Market Positioning & Client Base** METSL leverages deep-rooted relationships with Indian public health institutions and government bodies. Its growth is driven by successful bidding for high-value tenders and state-level healthcare mandates. **Key Institutional Clients & Recent Mandates:** | Date | Client | Product Supplied | | :--- | :--- | :--- | | **Feb 2025** | **DG Armed Forces Medical Service (MoD)** | METSL TFT Display Cardiac Monitor with Defibrillator | | **Jul 2024** | **DG Armed Forces Medical Service (MoD)** | Portable Multi-Channel ECG Machine (12-lead) | | **Jan 2024** | **Haffkine Bio Pharmaceutical Corp. Ltd.** | Multipara Monitor with NIBP (Neonatal/Pediatric) | | **Dec 2023** | **DGAFMS (DG 2S)** | Defibrillator Monitor with External Pacing | | **Nov 2023** | **ESIC** | METSL 2 channels TFT Multipara Monitor | The company also maintains a strong presence in the **National Health Mission (NHM), Jaipur**, providing diagnostic hardware across regional health centers. --- ### **Segmented Revenue Performance** In **FY 2024-25**, the company transitioned to a three-segment reporting structure to better reflect its focus on medical technology. Total revenue for the period was **₹28.89 crore**. | Segment | FY 2024-25 Revenue (₹ Lakhs) | FY 2023-24 Revenue (₹ Lakhs) | | :--- | :--- | :--- | | **Medical** | **2,704.75** | *Included in Telemedicine/E&I* | | **Telemedicine** | **170.30** | **244.52** | | **Electronics & Instrumentation** | **13.66** | **21.49** | | **Total Operations** | **2,888.71** | **3,328.93** | *Note: Fixed assets are utilized interchangeably across segments; therefore, assets and liabilities are not segmented.* --- ### **Expansion Strategy: Carebridge Technologies** A central pillar of METSL’s forward-looking strategy is the expansion of its technology and disease management footprint through its new subsidiary. * **Entity**: **Carebridge Technologies Private Limited**, incorporated on **October 9, 2024**. * **Capital Commitment**: Initially approved for **₹1 Crore** in July 2024, the Board increased the investment limit to **₹5 Crore** in **March 2025**. * **Objective**: To scale integrated healthcare technology solutions and enhance the company's digital health capabilities. --- ### **Financial Health & Capital Allocation** METSL has focused on optimizing its balance sheet by reducing debt and maintaining a disciplined capital allocation policy. **Key Financial Metrics:** | Metric (₹ in Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :---: | :---: | :---: | | **Total Revenue** | **28.89** | **33.29** | **24.60** | | **Profit After Tax (PAT)** | **4.38** | **4.94** | **2.58** | | **Working Capital** | **28.15** | **19.75** | - | | **Total Borrowings** | **3.60** | **5.35** | - | | **Trade Receivables** | **3.51** | **15.72** | **10.05** | | **Net Worth** | - | - | **24.03** | **Liquidity & Capital Structure:** * **Debt Reduction**: Total borrowings were reduced from **₹5.35 Crore** in March 2024 to **₹3.60 Crore** in March 2025. * **Equity Issuance**: In FY 2024-25, the company generated **₹1.00 Crore** from the issuance of shares, contributing to a net cash flow from financing activities of **₹60.52 Lakhs**. * **Dividend Policy**: The company currently follows a **zero dividend distribution** policy to conserve capital for expansion. * **Working Capital**: Sanctioned limits of **₹8.58 crore** are secured against current assets and collateral (land, building, and FDs). --- ### **Operational Infrastructure & Risk Management** METSL operates a structured risk framework overseen by the Audit Committee and Senior Management to mitigate market and operational volatility. **Risk Mitigation Framework:** * **Credit Risk**: Managed via the **Expected Credit Loss (ECL)** model under **Ind AS 109**. Exposure was significantly reduced from **₹15.72 Crore** in 2024 to **₹3.51 Crore** in 2025. Average credit terms are **90 to 180 days**. * **Foreign Currency Risk**: Classified as **very limited**. The company uses **Forward Exchange Contracts** (90-180 days) for imports but prohibits speculative derivative trading. * **Market Threats**: The company faces intense competition from **low-cost imported products** and rising **manpower costs**. METSL counters this by focusing on **operational efficiency** and rural development initiatives. * **Infrastructure**: The **Mahape, Navi Mumbai** facility serves as the primary hub for manufacturing and R&D, supported by a regular physical inventory verification program. --- ### **Future Outlook & Opportunities** METSL is positioned to capitalize on the **growing preference for online healthcare platforms** and the Indian government's push for **rural health development**. By leveraging its maturity in specialized medical electronics and its new subsidiary, the company aims to sustain its growth trend while maintaining a lean, low-debt financial profile.